Cancer medicine
Efficacy and Safety of First-Line Treatment Options for Oncogene Wild-Type Lung Adenocarcinoma With Liver Metastases
By Li J, Ge Y, Liu Q and 7 others.
Abstract
Objective
Liver metastasis represents one of the frequent drivers for cancer-related mortality in lung adenocarcinoma. For advanced lung adenocarcinoma harboring wild-type oncogene drivers, chemotherapies in combination with immune checkpoint inhibitors (ICIs) and/or bevacizumab (named IC, BC, and IBC, respectively) are alternative first-line schemes as recommended by canonical treatment guidelines. However, due to the immunosuppressive tumor microenvironment in the liver, patients with liver metastases are less effective to ICIs. For this subpopulation, the optimal regimen is still undetermined.
Methods
In this retrospective multicenter cohort study, treatment-naïve lung adenocarcinoma patients with wild-type oncogene drivers and liver metastases were enrolled from 4 cancer centers between January 2018 and December 2023. All these patients received BC, IC, or IBC as the first-line therapies. Propensity Score Matching (PSM) was applied to balance baseline covariates. Kaplan-Meier survival analysis, log-rank tests, and Cox proportional-hazards regression were used to compare PFS and OS among groups.